Jump to content



Recommended Posts

  • 2 years later...

Health authorities rely on widespread testing to find and treat people with the disease, and isolate them to prevent further spread of the coronavirus. One of the defining features of Genetic Signatures' test is its ability to detect the virus before a person has symptoms.


The speed and accuracy is another of the technology's advantages. While traditional testing can take three or more days to provide a result, Genetic Signatures technology can provide results in three to five hours.


The benefits for clinicians and healthcare systems is the ability to rapidly, accurately and simultaneously screen for a wide array of pathogens and their subtypes, says Genetic Signatures CEO John Melki. It can also be used in a range of diagnostic testing machines, meaning hospitals and professional labs don't need to buy expensive equipment to use it.


Genetic Signatures was founded in 2001 by Chris Abbott, who also co founded the respected funds management firm Maple Brown Abbott, and the late Dr Geoffrey Grigg, formerly head of molecular biology at CSIRO. Genetic Signatures has developed and commercialised a range of products that provide hospitals and pathology labs with the molecular tools to rapidly screen for an array of infectious pathogens.


The company, which listed on the ASX in 2015, is based in Sydney, which is also home to its manufacturing facilities. The business was first funded by founders and private investors, but as it has achieved development milestones, it has raised capital from private and institutional investors to support its global expansion.


Melki says the pressure worldwide to move away from lockdowns and get back to work prompted demand for accurate testing of entire populations, which has driven demand for his product.


Many Western governments are turning to mass testing for the coronavirus, hoping that quickly isolating more new carriers will halt its spread and allow the reopening of their economies, he says. With the economic cost of lockdowns rising, health and government officials in Europe and other countries are looking to follow the example of South Korea, Singapore and Taiwan, where millions of people have been tested .


More than 2 million COVID-19 tests have been conducted in Australia alone, according to the federal Department of Health. But this pales in comparison to the US, where more than 31 million tests have been conducted, according to John Hopkins University.


Melki says Genetic Signatures is well positioned to help governments and stressed healthcare systems address the pandemic. Until a vaccine is found, mass testing is going to be the key to identifying and controlling outbreaks of the virus within communities globally.


The pandemic has accelerated the company's business expansion plans. It has allowed it to enhance its relationships with labs and hospitals around the world and demonstrate it is a reliable long-term partner in addressing global health challenges. All Genetic Signatures staff are tested at least three times a week to ensure there is no threat to maintaining the supply of its essential equipment.

Link to comment
Share on other sites

  • 1 year later...

and that was about as good as it got ... $2.60 in July 2020 but back to about half than, now.


For early days cash starved minnows in the tough world (Genetic Signatures Limited (GSS) is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base. The company deals in the the research and commercialisation of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces) then GSS has to get some runs on the board, eyeballs, interest, results.


Maybe the webinar this week has something to say??

Link to comment
Share on other sites

  • 4 months later...

from $1.30 just before XMas, trading has picked up and now is $1.80

Half Year Sales

Genetic Signatures has had a strong year to date and expects sales of at least $21m for the half year. First quarter sales were a company record $12.4m supported by a surge in SARS-CoV-2 testing in Australia. The recent emergence of the Omicron variant has seen testing volumes increase dramatically in the past two weeks. This increased testing will likely continue into 2022.

SARS-CoV-2 Update

At the beginning of December a new, highly transmissible SARS-CoV-2 Omicron variant was identified and classified as a variant of concern by the WHO. Genetic Signatures determined via in silico analysis that the current EasyScreen™ SARS-CoV-2 Detection Kit was able to detect all known variants, including the Omicron variant and has advised its customers.

Since then, a new detection kit has been developed, the EasyScreen™ SARS-CoV-2 Variant Detection Kit. This was designed in collaboration with customers to differentiate the Omicron and Delta variants prior to sequencing. Performance of the new kit has been confirmed in-house against more than 300 clinical patient samples. The new kit is being offered initially as Research Use Only and can identify mutations specific to Delta or Omicron in SARS-CoV-2 positive samples. The test can be used either in parallel with, or as a reflex test to the primary screen. 

................. a rapidly moving field. Admittedly there has been a holiday break, but there have been no updates since.

Until today:

GSS advises that the Therapeutic Goods Administration (TGA) recently registered a saliva based protocol for collecting and testing patient samples for SARS-CoV-2 using the Company’s 3base® EasyScreen™ SARS-CoV-2 Detection Kit.  A recent study from scientists in South Africa demonstrated that saliva swabs could be more effective than mid turbinate nasal swabs in detecting the Omicron variant in PCR based tests, due to a higher viral RNA load in saliva than in nasal samples. This is different to other variants such as Delta that are more reliably detected from a nasal swab.

Dr. John Melki, Genetic Signatures CEO, commented:


Our team is driven to provide our customers with the highest quality tests and are constantly looking at ways to improve our products so they remain effective in detecting pathogens. We are pleased that this study and subsequent registration has been completed so quickly. With Omicron becoming the dominant strain of the SARS-CoV-2 virus it is likely that this new methodology will be needed to identify all cases of this new variant.


Link to comment
Share on other sites

  • ShareCafe Admin changed the title to GSS - GENETIC SIGNATURES LIMITED

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...